Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 50
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101621-101621
Open Access | Times Cited: 31
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 7
Open Access | Times Cited: 16
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components
Peng Zhang, Yuting Wang, Qianru Miao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115569-115569
Open Access | Times Cited: 24
CD8+ T cell exhaustion in the tumor microenvironment of breast cancer
Hanghang Xie, Xiaowei Xi, Ting Lei, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Leona Rašková Kafková, Joanna Maria Mierzwicka, Prosenjit Chakraborty, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 9
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
Amalia Azzariti, Simona De Summa, Tommaso Maria Marvulli, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
MariaLuisa Vigano, Lixing Wang, Alia As’sadiq, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14496-14496
Open Access | Times Cited: 32
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Tianye Li, Xinrun Wang, Mengke Niu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients
Songyun Zhao, Qi Wang, Kaixiang Ni, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Progresses in biomarkers for cancer immunotherapy
Xuwen Lin, Chenyu Zong, Zhihan Zhang, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 20
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Reliable Detection of Extracellular PD-L1 by DNA Computation-Mediated Microfluidics
Yuqian Zhang, Qiuyue Wu, Yihao Huang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 24, pp. 9373-9379
Closed Access | Times Cited: 18
Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
Lianxiang Luo, Tong Wu, Miaorong Ji, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112098-112098
Closed Access | Times Cited: 6
Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
Wenjiao Xia, Jiaxin Chen, Wenqing Hou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6843-6843
Open Access | Times Cited: 16
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, et al.
Journal of Cancer (2023) Vol. 14, Iss. 5, pp. 850-873
Open Access | Times Cited: 16
Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
Dingyu Rao, Defa Huang, Mao-Yan Si, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion
Mingcang Chen, Zhengwei Fu, Chunyu Wu
The International Journal of Biochemistry & Cell Biology (2024) Vol. 175, pp. 106637-106637
Closed Access | Times Cited: 5
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
Jair Bar, Raya Leibowitz‐Amit, Niels Reinmuth, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma
Xipeng Wang, Wei Guo, Ye-Fan Chen, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112074-112074
Closed Access | Times Cited: 4
Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy
Xiyao Chen, Boxiang Zhang, Xin Song, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 5, pp. 593-603
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top